<SEC-DOCUMENT>0001144204-13-055147.txt : 20131015
<SEC-HEADER>0001144204-13-055147.hdr.sgml : 20131014
<ACCEPTANCE-DATETIME>20131015120148
ACCESSION NUMBER:		0001144204-13-055147
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131008
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131015
DATE AS OF CHANGE:		20131015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		131151002

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v357340_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-indent: 31.9pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):&nbsp;&nbsp;October
8, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SYNTHETIC BIOLOGICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">Nevada</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">1-12584</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(Commission File No.)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">155 Gibbs Street, Suite 412, Rockville,
MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)&nbsp;&nbsp;(Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;(734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.2pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 1.1pt; text-align: justify"><FONT STYLE="color: black">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD>
    <TD COLSPAN="4" STYLE="padding-right: 3.3pt; text-align: justify"><FONT STYLE="color: black">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; padding-right: 2.2pt; text-align: justify"><FONT STYLE="color: black">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8.01. &nbsp;Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">On October 15, 2013, Synthetic Biologics,
Inc. (the &ldquo;Company&rdquo;) issued the attached press release that included information related to </FONT>the successful completion
of the protein expression evaluation by FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm) with regard to the Company&rsquo;s
proprietary oral beta-lactamase enzyme (SYN-004) targeting the prevention of <I>Clostridium difficile (C. difficile</I> or<I> C.
diff)</I> infections and the manufacturing of SYN-004 material to support Synthetic Biologics&rsquo; planned preclinical and clinical
studies pursuant to an agreement with Fujifilm entered into on October 8, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release is attached as Exhibit 99.1 to this
Report on Form 8-K. The information contained in the press release is being furnished to the Commission and shall not be deemed
incorporated by reference into any of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01.&nbsp; Financial Statements
and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">The following exhibit
is being filed as part of this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 86%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-indent: 31.9pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="color: black">99.1</FONT></TD>
    <TD><FONT STYLE="color: black">Press release issued by Synthetic Biologics, Inc. dated October 15, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Date: October 15, 2013</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">/s/ C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Name:&nbsp;&nbsp;C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Title:&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 86%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-indent: 31.9pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="color: black">99.1</FONT></TD>
    <TD><FONT STYLE="color: black">Press release issued by Synthetic Biologics, Inc. dated October 15, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v357340_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Synthetic Biologics Initiates Manufacturing
of SYN-004 for Use in Preclinical and</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Clinical Trials to Target the Prevention
of <I>C. difficile</I> Infections</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>-- Company&rsquo;s Proprietary Oral
Beta-Lactamase Enzyme Successful Evaluation Conducted by </I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>FUJIFILM Diosynth Biotechnologies
UK Limited --</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: windowtext"><B>Rockville,
MD, October 15, 2013 &ndash;</B></FONT><FONT STYLE="font-size: 10pt; color: windowtext"> Synthetic</FONT><FONT STYLE="font-size: 10pt">
Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases,
announced today the successful completion of the protein expression evaluation with regard to the Company&rsquo;s proprietary oral
beta-lactamase enzyme (SYN-004) targeting the prevention of <I>Clostridium difficile (C. difficile</I> or<I> C. diff)</I> infections,</FONT>
America&rsquo;s most prevalent hospital-acquired bacterial infection<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FUJIFILM Diosynth Biotechnologies UK Limited
(Fujifilm) analyzed and demonstrated a greater than 20-fold improvement in SYN-004 expression titers with consistent biological
activity utilizing its pAVEway&trade; platform (an <I>E. coli</I> system) compared to the Bacillus platform previously employed
by Ipsat Therapeutics Oy (Finland) for the expression of P1A, a first-generation candidate of SYN-004. Pursuant to an agreement
entered into with Fujifilm on October 8th, manufacturing of SYN-004 material to support Synthetic Biologics&rsquo; planned preclinical
and clinical studies is underway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-004, a novel second-generation oral
drug candidate in preclinical development for co-administration with commonly used IV antibiotics, is intended to prevent the development
of severe effects of <I>C. diff</I> infection<I>,</I> which is extremely harmful and potentially deadly. Designed to be given orally
to protect the gut flora (microbiome) while certain IV beta-lactam antibiotics (penicillins and cephalosporins) fight the primary
infection, SYN-004 is believed to have a similar profile to its first-generation predecessor, which demonstrated favorable protection
of the gut flora during <FONT STYLE="color: black">treatment with certain penicillins,<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[1]</SUP></FONT>
with the potential to act against </FONT>a broader spectrum of IV beta-lactam antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We&rsquo;re very excited to be working
with the dedicated team at Fujifilm. With the SYN-004 production cell line evaluation and selection of the <I>E. coli</I> expression
clone successfully completed, we have initiated manufacturing of preclinical material for animal studies and cGMP production of
SYN-004 for clinical trials,&rdquo; stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. &ldquo;We are pleased
that these efforts move us closer toward our goal of developing a prophylactic to prevent the devastating effects of <I>C. diff</I>
infections, for which there is currently no other approved preventive therapy. We look forward to announcing the initiation of
preclinical studies during the first half of 2014, after which we plan to initiate our clinical trials.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steve Bagshaw, Managing Director of Fujifilm
Diosynth Biotechnologies UK Limited said, &ldquo;We are delighted that the pAVEway&trade; study performed in our R&amp;D laboratories
has produced such a successful improvement in titers. We now look forward to performing further process optimization before scaling
up in our pilot scale laboratories and ultimately producing cGMP material to allow Synthetic Biologics to carry out clinical trials
in the fight to provide a drug to counteract the effects of <I>C. difficile</I> infections.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About <I>Clostridium difficile (C. difficile,
C. diff)</I> Infections</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CDC recently identified <I>C. diff</I>
as an &ldquo;urgent public health threat,&rdquo; particularly given its resistance to many drugs used to treat other infections.<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[2]</SUP></FONT>
<I>C. diff</I> infects 1.1 million Americans each year,<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[3]</SUP></FONT>
and 30,000 patients die with a <I>C. diff</I> infection annually.<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[4]</SUP></FONT>
This opportunistic infection adds an estimated 4-7 extra hospitalization days per patient,<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[5]</SUP></FONT>
and is associated with $8.2 billion in overall annual hospital costs.<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[6]</SUP></FONT>
<I>C. diff</I> infection is strongly associated with the use of IV antibiotics, which are administered to more than 24 million
Americans annually.<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[7]</SUP></FONT> When IV antibiotics are given to
prevent or treat an infection, they can create a harmful imbalance in the gastrointestinal (GI) tract by wiping out helpful &ldquo;good&rdquo;
bacteria, which can allow <I>C. diff</I> to quickly grow out of control causing severe diarrhea, damaging the colon and in some
cases, leading to death.<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>[8]</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Fujifilm Diosynth Biotechnologies (http://www.fujifilmdiosynth.com)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FUJIFILM Diosynth Biotechnologies UK Limited
is an industry leading biologics Contract Development and Manufacturing Organization. Fujifilm Diosynth Biotechnologies has extensive
experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules
expressed in a wide array of microbial, mammalian, and insect systems. The company offers a comprehensive list of services from
microbial and mammalian cell line development, including its proprietary pAVEway&trade; system, to process development, analytical
development, clinical and commercial manufacturing. Fujifilm Diosynth Biotechnologies is also located in Research Triangle Park,
NC, USA as FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Both sites have been FDA-approved for the production of commercial biologic
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases.
The Company is developing an oral enzyme for the prevention of<I> C. difficile</I> infections, and a series of monoclonal antibody
therapies for the treatment of Pertussis and <I>Acinetobacter</I> infections. In addition, the Company is developing a drug candidate
for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information,
please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To download Synthetic Biologics&rsquo;
investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please
click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding our intention to develop and
commercialize a proprietary oral beta-lactamase enzyme product candidate to prevent C. difficile infections, our intention to commence
clinical trials and the expected size of the market for C. diff therapeutics. The forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics&rsquo; forward-looking
statements include, among others, Synthetic Biologics&rsquo; inability to timely manufacture cGMP material</I> <I>or commence or
complete the clinical trials consistent with its current expectations and Synthetic Biologics&rsquo; inability to successfully
develop, receive regulatory approvals for or to commercialize a new product candidate to prevent C. diff infection and other factors
described in Synthetic Biologics&rsquo; report on Form 10-K for the year ended December 31, 2012 and any other filings with the
SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Corporate Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(734) 332-7800, ext. 22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">_______________________________<FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>[1]</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">Tarkkanen A, Heinonen T, Jogi
R, et al. P1A recombinant &beta;-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects
during intravenous administration of ampicillin. Agents Chemother 2009; 53 (6): 2455-2462.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>[2]</SUP></FONT></TD><TD STYLE="text-align: justify">U.S. Centers for Disease Control Web site: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf#page=51
Accessed: September 30, 2013.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[3]</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">This information is an estimate
derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital
database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[4]</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">U.S. Department of Health
&amp; Human Services. Agency for Healthcare Research and Quality. January 25, 2012. </FONT>http://www.ahrq.gov/news/nn/nn012512.htm
<FONT STYLE="color: black">Accessed: September 30, 2013.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[5]</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">(APIC) National Prevalence
Study of <I>Clostridium difficile </I>in U.S. Healthcare Facilities. November 11, 2008.</FONT>http://hospitalacquiredinfections.blogspot.com/2008/12/november-11-2008-association-for.html
<FONT STYLE="color: black">Accessed: September 30, 2013.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>[6]</SUP></FONT></TD><TD STYLE="text-align: justify">Agency for Healthcare Research and Quality. Healthcare
and Cost Utilization Project. Statistical Brief #125. Clostridium difficile Infections (CDI) in Hospital Stays, 2009. January
2012. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf Accessed: October 1, 2013.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>[7]</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">This information is an estimate
derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital
database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>[8]</SUP></FONT></TD><TD STYLE="text-align: justify">Committee to Reduce Infection Deaths Web site http://www.hospitalinfection.org/preventing_cdiff.shtml
Accessed: September 30, 2013.</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``Z`1H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_**Q_'GC
M>R^'7A2\UC4686UFF2J#+R,3A44?WF8@#.!SR0,FOFD>+O&W[37B-[6&[FTS
M2G<J+6UD9(57J0Q&#(0,$EOE!Y`!(6J2N)L^G;_Q-I^EM(MS?64#11M*XDG1
M"B*-S,<G@``DD]`*CT#QEI/BR$2:7JFG:FA`;=:W23@@C@_*3V/ZUY?X;_8S
M\-66@75AJIGU.'48UCO("VV*=58.%88YPP!!`4C':L+4O^":7POO9WEBL]5L
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M'7(92.A!Q5VNIGC:]0HHKPK_`(*6_M27_P"QE^Q)X]^(NDVT-WK6B6D<&F1S
M+NB6[N9X[:&1Q_$B/*'*Y&X(5R,T@/6?&_Q-\/?#+3$O?$NO:+X>LW)"SZG?
M16D3$#)`:0@'`IG@7XI^&_BA827?AGQ#H7B.UB(#S:7J$5Y&F>1EHV(&17\^
M7[`7_!/'QO\`\%JOBMXY\6^,OBC/;3^'3:_VGK&J6SZQJ5[)<&4QPPQF2-8H
M56)\88(GR*D9&=FA^WQ_P2$^)/\`P2JUSPIX[\$^,M5\36U]>-:6VM>']/GT
MK5M&N@C2*C+#)(?+=$;$BN`2K*R#*[G8#^AC[5&&*EU!'4%AFGJ^\`@@@C/7
M-?AU^U_\"->_X*G_`/!,3P]^T?J/AGROC/\`"M+G1/&(.F&UE\1Z;;-O-T(B
MH`>*.1;C"A5Q)=*HXC4>J_\`!M?_`,%"QJNA7'[/7B>]!N=,CEU+P7+(P'FV
MPR]S8`]S&2TT8&?W;2CA8E%`'ZX22"-<L0!ZDX%,-W'_`,]$)'^T*_"7_@XB
M_;Y;]I3X\6_P4\+2MJ'A3X?7VW4TMU,HUC7/]68@HSO%ON,2@#)F>48.U#4_
M[='_``3<T[]@'_@B=X3LM6TRQ'Q!\9^/-,U7Q3,L:,89?L&H>39!@.4MT8KU
M(,CS..'P`#]U8Y1*,@A@/0YI9)/+&21^)P*_G0_X(?\`_!0Z/]@O]I5=$UZZ
M2U^&7Q"EBLM:!PL.E7>=MOJ'8*%)\N4\9B;<<^4HK]??^"Y<:7?_``2D^,".
MJ2HUA9Y##<K?\3"UH`^K_M:==Z8Z?>%+]JC_`.>B?]]"OYWO^"8'[`6M?\%`
MOV.OC7X!\*WOAK1=0@\4^&-7>;54D6V:.*#5D*_ND<[LRC'&.O-8O[=7_!##
MQS^P%\"F\?\`BG7OA]K&EKJ-OIOV?2EN#<%YBVUOWD*KM&TYYS0!_1W]JC_Y
MZ)_WT*3[4FW.]",X^\.M?S3_`/!/;_@CCXN_X*/^!/$7B#PCK'@;1+;PWJ2Z
M9<1:NDZR2.T*RAE\J)QMPX')!R#Q7LO[=W_!-/Q%_P`$XO\`@ED?#7B[4O"F
MN7'B?XM6&JV[:.DK0Q(FC7T1#^;&AW9!/`(QWH`_?6.42C((8>H.:5W$8RQ`
M'J3@5^<7_!KW:Q6?_!/KQ0D4:1*?'U\<(H49^P:?Z5WO_!Q3;1W?_!*CQJDJ
M+(AU71LJP!!_XF5OZT`?;HN5*D[E('4[A@4OVJ/_`)Z)_P!]"OYW_P!A'3+:
M'_@CE^VA&MO`J2'P[N58P`W^E'&1WKRC_@GA_P`$LO$G_!236/%ECX0U+P=H
M<WA"&UGN3K$<JB=;AI579Y4;]#"V<XZC&><`']._VJ/_`)Z)_P!]"D^U)P2Z
M<]/F'-?A5_Q"K_%W_H<_A)^5[_\`(]=U\1O^#:SXH>,_@O\`#'PQ!XM^&"7?
M@:TU2WNI)1=^5,;K49+I#'BWS@*X!R!\P.,CF@#]G/M4?_/1/^^A1]JC_P">
MB?\`?0K^7C_@H+_P34U[_@G+\0?#_ASQ=?\`A/7+SQ%ISZE!)I$<ACB193&5
M;S8T.XD9X!&*]Y_9M_X-S_B1^T]\!O"?Q!T7Q1\,K'2O%^FQ:G:V]ZMT+B%)
M!D*^R`KN'?!(H`_H.^TH,9=1GD98<TL<GF#(((/0@Y!K^=__`(+2?LS7?[*_
MAK]FSX<Z\^CZGJO@_P`!7%A/<62,UM(POW;,>]5;;\W<#FOO7P_^W];?\$Y_
M^"#OP8\2V-I97_B[6_#]IH_AG3Y\^0]TR.[3RJI#&"&-&=@N-S"./<AD#``_
M1GQ;XVT?P#I!U#7=6TW1K!6"&YO[J.VA#'H-[D#)P>,UG?#_`.,GA/XL02R^
M%O%'ASQ-'!S(^DZG#>K']3&S8K^?+]E+]@3XY_\`!;/XDZYX[\1^+WETW3[D
MVM_XK\2%[E4F8"0VEE;)M7"AT8Q1^3#&KC!!(4[O[=/_``1,^*7_``3-\,0_
M%7PUXTA\3:'X=GB,^O:'%-H>L:`[N$2?8LKLL>]D4R13%E+C*A06`P/Z%:*^
M#O\`@@W_`,%*=8_;R^!6OZ%XVO$U#X@_#J:WBO;]42/^V+*X5_L]RRJ`HF#0
MS1R!0%_=H_!DVK]XT@/%_P!N-Y5^&.E*I81/JJ"3'0_N9<`^V>?J![4_]D6Q
MM[3PU(R!?.^RPN#W^<NS_P#CV,_05WOQC^'R_$_X>ZAHY9(YYU#VTC=(YE.Y
M"3@X!(P<<X8UXS\&O$]K\(;3P_%K>HG3M2O8[I9K*XMW_=PQW+1'<RY((<`C
MY<<<L`<UAB\=A\+1=7$S4(IK5NRU=EJ_,EM)W9]'453T37[+Q'8BYL+NVOK=
MNDL$JR)GTR#UJY6E.I&I%3@[I]5JBKA67XI\(Z;XYT.?3-7LK?4;"Y4K)#,@
M93[CN".Q'([5J45HFT[H:DTTT[-'Q=\0_"OB3_@FUXF3Q%X)GDUSX9ZO<DZC
MX7GF`>V<Y9Y+7/W'QDY4;6`PXR$:OJ7X0?&KPU\>/!]MKOAC5+;4[&X168(X
M\ZV8C/ERI]Z-QR-K8Z=QS6_K.C6WB'2Y[*]@BNK6Y4I+%+&LB.#ZJP(/X@U^
M77[)7[=]]^R3_P`%#?\`AGG7_#^G:?I.K>*=2TV_UFWD(74;N=;5=)N%A()M
MPRPE'B5W0R7X9?+6,1BL=F>'4(O$74V[)]'Z]GY];:GV>69+B^(,-7J86'-6
MH1<Y6:3E!7O)KJXZ+2[;:TZK]4J\\_:P_9LT/]K[]G?Q7\-_$CW$6D^*K+[,
M\\&/.M)%=9(9TSP6CE2-P#D$I@@@D5Z'^M?(_P#P6R^'/Q3\>?L-:C>_"#7O
M&.B^+/"6I0:[)%X8U.ZL-1U2SC26.>W1K=U>3"R^=Y>3O-N`%+;14GQ9^5?Q
M`_X(^?M>?L"_$"\U[X:_\)!KEM;`I'X@\`ZJT%U=0;MRI-9AUN&)P"T02:,'
MC<_!.C\/O^"^G[5G[+GB^/0_B1:6OB6>UVFYTKQAX<;1=56$'&%:%(&1C@C?
M+%+SG(8UW?\`P2)_X+TVG[._A'6?"/QUUKQ[XOLM0U$ZEI?BFYOI]>NK,/'&
MCVLWG2--Y(,>]/+WX:20%0,&M3_@M1_P5]^!G[9W[-4?@/P+I>K>*=>_M&WO
MK77[[2FL8-#2-]TIB,VV8R2*/+*A`A1V);*A6;`_3O\`8%_;G\)?\%%/V>;?
MQOX<M[BP=)WTW6M'O"LDVE7BJK/`Q'RR(4='1Q@.CJ2J-N1?Q$_X*Q?L5ZW_
M`,$NOVV;#Q+X"N+S0O"VOW3>(/!NH63E'T:='!FL@W8PLX*@Y#0RQ@EB'%?H
M+_P;+_L\^(OA9^R;XK\9:[;76GV?Q&U>&ZT:WF!4SV<$.Q;L*>0LKO(%)^\D
M2,,JRD^??\'5O_)/O@H,_P#,4U7_`-$6]+J!XY_P;M_\$\I/CG\9)_CEXPM)
M9_#7@:\*Z`MSEO[5UD?,UR=V2Z6P;<&[SNA!S$PKZS_X.>/^4?7AO_L?+'_T
MBOZ[;_@W78M_P2R\(YSQK&LC_P`J$]<3_P`'/'_*/OPW_P!CY8_^D5_1?4#\
MY?AW_P`$[)/VBO\`@CY??%WPM8B;QA\./%&J#5H(DS)J^CB&U=^@^:2V):5>
MYC:9?F.P#V+X5_\`!1IOVDO^"'WQB^$7BJ^,_C?X<Z)8MIL\K%I-8T9=1M$C
M<GO);EDB<]T:!LLQ<C[!_P"#9N/S/^"=6I@X(/C34001D$>1:5^;_P#P6H_X
M)XS?L"_M.3:CX9MYK3X:_$0S7>BF%BL>G2D@W.FMC&%0MOC4\&)@OS&-S3ZV
M`^N?^#4P_P#$G^.O_7QH?_H%_7N__!RG_P`HV6_[&O3/YRUX1_P:F?\`('^.
MO_7QH?\`Z!?U[O\`\'*?_*-EO^QKTS^<M#W`\S_X-7_^3;_BM_V-</\`Z0PU
MTG_!T1_R8MX)_P"Q]M?_`$WZA7-_\&K_`/R;?\5O^QKA_P#2&&ND_P"#HC_D
MQ?P3_P!C[:_^F_4*74#\WOV#_'O[9'A?X.W]O^SVGCM_!3ZO+)=G1=$L[VW^
MWF*$29>:%V#^6(<@'&-IQDG.Q^V;\1/VXO$G[/NK6GQQC^(B_#AY[5K\ZMH%
MC:6@E$Z&WW210JX/G>7C#`$X!STK]%?^#83_`)1_>*/^Q]O?_2#3Z[W_`(.(
M?^45OC7_`+"NC?\`IRMZ?4#\P?V%?^4.W[9WU\._^E1KS/\`X)Q?$K]ICX<Z
MQXO?]F^RUV\O+N&T7Q!_9NAVFJ,B*TWV?=Y\;[`2TV-N-V#G.!CTS]A7_E#M
M^V;]?#O_`*5&J'_!&O\`X*;^$O\`@FOXF^(-_P"*_#OBGQ"GC"UL(+5=%6V9
MH#;O<,QD\Z6/@B9<;<]#G'%'<#VL_M/?\%0\'_B2^/L_]B+I/_R/7Z[?L=:S
MXT\1?LL_#Z_^(T=U%X]O-!M)?$"7-M';3)>F(&8/%&%1&W9RJ@`=A7P?_P`1
M3/P@_P"B:_%?_OUIO_R77V5^P!^W=X=_X*'?!"Z\=^&-%U_0=.M-7FT=K;5U
MA%PTD4<3EQY4DB[2)0!\V<@\=*3`_+'_`(.EO^3J?AA_V*D__I8U?IE_P2*_
MY1E?!#_L5+3_`-!K\S/^#I4Y_:H^&'_8J3_^EC5^F?\`P2*_Y1E?!#_L5+3_
M`-!H`_,__@Z9_P"3HOA;_P!BM<_^E9KP_P#X*7ZM?2_L*?L2V$F\:;#X#U"X
MA'17F:6S5_J0J1]>F\XZFO</^#I<Y_:A^%O_`&*US_Z5FO1?C?\`\$_]9_;8
M_P""$GP`UCP=82:GX[^&V@1ZCI]C$`9M4LYD"W=K%ZRD1PRJ.KM;A`,N"'<#
M[!_X(7:)INB?\$KOA.--,;)=VM[=7#H.7N'O[DS;CU)5\IST"`=``/J3Q?IV
MEZOX:OK;7(-/NM'F@<7L5_&CVKQ8RWF!_E*XZ[N*_"3_`()!_P#!;J']@7P#
M>_#/XC^']>USP5!?S7.F7.EJC:AH,TC_`.D6SP2N@:$R[I.&62.1I?ED#@1^
MA?\`!5[_`(+^>%/VG?V;M:^&'PJT7Q);6WBN,6NNZYK4,=HJ66Y6D@MXED=F
M,H4QNT@4+&S@!BP9%9@?KG\+/"GPY\,:C=MX*TWP187DT2BZ.AV]K#(\8/RA
M_)`)4$G&>,FNXK\OO^#:;]A76/@;\(?%7Q8\3:2^D7OQ)CM;;0;>>#RIQI<.
M]_M)!P0MQ)("H8<I;QN,K("?U!H8!7SS^UY^ROXD^+_B6#Q;X:UR&+6=$T]+
M:RTN:';'=$22/)F8M@%U=5"E=OR<L`V4^AJ*\O.,HPV9X66$Q:O!]FUKT>G;
MSNNZ,J]&-6'),^#?@9^TW=?"OQQ>6UYI"V6N0C[/JFD7T7DW2@<YB<C<!T;N
M"""0?E:OKKX8_M"^%OBQ$D>F:BD6H,.;"Z(BNE]<+G#@>J%A[UG_`![_`&6?
M!W[1VEQQ>)-/<7]J,6FJ6;^1?V7)(V2`'(!).UPRYYVYYKY+^*O[!_Q7^&+R
M3>')=/\`B7H\9W1QO*NGZO$!S@[SY4FT?Q;MS$<*.E?F^$RS/^&;TL$EB<-=
MM1VE&_;K]W,NME<\N<\7AMH\\?+?[O\`*Y]^45^7=Y^W#\1/V>9!9Z[?>//!
MQ5O+$/B'3'EB..,1M,C@KQP4P,=*Z;X4_P#!6VY\0?$O0;'Q%\0?#>E:!-=+
M]OO)=,*;8ERQ4MLPA?;LW$`*7!X`KW\)X@86K.-&M1J0FVE9I63?G=:=VTCF
M7$N'YU3G&2;TV7YW/T%\9>,M)\"^%]0UK6]0M=,TG28FFO+J>0)';H!R2>QZ
M8'4D@#)Q7X*?M/\`@KQK\1_VUK/QAH,7BWX@R:Q<V/B?1-6T[19;F]NK)'18
M&DBMHN+B`VS0RA5'[ZVD]0:]Q_:A\0^./$MCXA\57=C>:MX9UG59]5-[8:DF
MJ>'897`"N)K:22`LL01`696VH`>A%?0'_!*[_@FY\1?AWXELO'7Q,\6^(K31
M;.5M2T'P1!KDLFG_`&F4'_3KF"-S;[@K;HT4,0Q5V*LH6OV3B7@#`O)X8NIC
M5S.2<>6TE+36*L]7=K6Z27J5X(_2-S?+N)L50HY0W1E2E3E[2\9*\DXS;<+Q
MBU%^YO)V_E5OT%T36X?$.CVM_`EW'!>PI/&MS:RVLZJPR`\4JK)&V.JNH93P
M0#Q5ZBOFC_@KTP'[!'B=7^PLDVL^'(G2^G,%I*CZ_IRLD[@$K"P)5S@X0MP>
MA^7/H96N[;$_[0G_``2+_9U_:A\57.O>+_ACH\NNWKM-<ZCI=Q<Z/<7<K9S+
M,UI)%YSG/WI0QZ5@_"G_`((A?LO?!WQ!!JNG?"G3-2O[<AD;7;^\UF$,.C>1
M=320[@>0=F00#U`KC?\`@GTMEX(_;<^(_AW3K+P!HNG:CX1TO4X=&^'>OOJW
MAZR>.[NXI)[H/%%]GO9_,14"1!9(K5B69HR%^X*=Q#8X_+``Z#@`#`%>:_M)
M?L;_``R_:^L=(MOB5X0T[Q;!H,DDU@EVTJBV>0*KD;&7J%4<YZ5G?\%`IFMO
MV#OC;,DC1/%X!UUE=6VE"-.GY![$>M>@_#-BWPZT`DEB=-MCDG)/[I:5P,KX
M$_`'P?\`LR_#FU\(^!-"M/#?ARREEG@L+8N8XWED,DC#>S'+.Q/7O53]H?\`
M9C\!_M8>![?PU\1/#=CXJT.UO4U"*SNFD5$N$1T60;&4Y"R..N/F-=Y7R-\:
M?"_@'XL_\%`-1\,_&J/0]1\,67@>RU#P7HGB-T.C7]P;J]75;I89?W,UU"BV
M"[FR\,<H90HE9F`/?_V>_P!FGP-^RIX%E\,_#WPY9>%]"FNWOWL[4N8VG=55
MY/G9CDA%'7'%/_:`_9O\#?M3^`1X7^(7AK3?%6@BYCO5M+Q6*QS1YV2*RD,K
M`,PRI&0S`Y!(/F'_``3-UZ37?V?-5^Q:G>:WX,L/%FLV/@O4;FZ>[:\T**\=
M;4I.[,\T"8DCAE9F+PQ1,"P(8_0U`'E_[-?[%_PO_8_BUF/X:^#M,\))XA:%
MM1%FTK"Z,(<1EM[-]T2/C&/O&MGX_P#[./@G]J;P#_PBWQ`\/67B?0#<QWGV
M*Z+B/SH\['^1E.1D]^]>7_MP>*[+P9\8?V<+[4]3M=)T]/B'.MQ<75TMM`JG
MP[K.`[,0N"VW`/4X[U[KX4\8Z3XYTD7^BZIIVL6)8QBXL;E+B$L.J[D)&1W&
M>*+@<5^SA^R-\./V1-!U/2_AOX4T_P`*6&L7(O+R&T:1EN)@@0.=[,<[0!QZ
M58_:+_9;\`?M:>#;/P]\1O#-CXJT:PO5U&WM;MI%2.X5'C$@V,IR$D<<G'S&
MN_KY>_;EM?#_`(J_:*^"WACXDW$$?PGUY]7^VV=_-Y6D:WKD<=L=-L;W=A)4
M:(ZA*D$AV220(2K,BB@#V3]G?]F'P'^R=X(N?#?P[\-6/A;1+N]?49K2U:1D
M>X=$1I#O9CDK&@ZX^45=^.OP#\'_`+3/PWN_"'CO0K3Q)X;OI8IKBPN6=8Y7
MBD62,DH0?E=5/7M7B7[!7]C:%\;/C;X9^'UU%<?"/PYJ.FQ:-!93"?2]'U5[
M9WU2PLF#,J01_P"ANT,9$<4T\ZA5.Y1].T`>&>#?^":?P,^'WPK\6>"-&^'6
MB6'A7QSY']NZ<CSF+4O(;=%O)D+#:W(VD5Q__#E7]EO_`*(WX:_[_7/_`,=K
MK/\`@I/XDOO"G[(FNWD&HZGHNEG4=)@\1ZGITTD%WI>A2:G:QZK<QR1_/&8[
M%KEC*I5HU#2`@H*\:_9_F^'GP9_X*):-X/\`AWX?\`^&]+\5>$=0NX8_!/C,
M7-OK%K;O9-#?:GI2V:11W!:618+I+EY)$-P&:0`"-W`[G_ARK^RW_P!$;\-?
M]_KG_P".U[3^SU^S/X%_92\#2^&?A[X<LO"^A3W;W[V=JSLC3NJ*\GSLQR0B
M#KCY:[JD(SC/:E<#R#]HO]@7X/\`[6WB/3M7^)'@72O%FI:3;&SLY[MYE:"$
MOO*#8ZC&XYYKT'X7?"_0?@O\/](\*^&--@T?P]H-LMGI]C"6,=K"OW4&XDX'
MN2:\O_X)I7#W?_!/3X(S22O,\O@C2&9V8L7)M(R22>M>WT7`\@_:+_8&^$'[
M6_B'3M6^)'@;2O%FHZ1;-:6<]V\JM!$S;R@V.HP6YYKT#X6_"W0?@K\/M(\*
M>%]-@T?P]H-LMGI]C"6,=K$O1!N).![DU\Y_M@V'ACQS^VE\)?"/Q3_LN;X8
MZMH&N75EIFKRJ-'U[Q#%-8>1;W4;GRIWCLWO)889`RMB>0*6@4KWG["2^`K+
MP#XLT[X8ZCKFI>"M(\5WUE8_:IQ<:99R(L/VBVTJ0=;"*<RHJ[F6.5;B-"$C
M1%`,[]I+_@EE\`OVM_$DNM>._AMHVI:[.0T^J64L^E7UT0H53-/:21/-@``>
M86P`!TKF/@O_`,$5/V9?@/XHM];T7X6Z9?:K:,'AFUR]N]92%P<JZPW4LD2N
MIP0ZH&!`.<@&OJ>OFO\`X*?Z3IWB;X3>"=&U3Q-X>T"#5_&EE!'9^)8)W\.>
M)Y5@NI4TK4WB9?*MYC'E6D)C:XCMHRDOF"&1W`^E**^7O^"8^K:;8:?\5/".
MG>']-\,/X1\6+%=:7X>\1?V[X5TZ6?3[.<PZ3*8(&MX<,)9+1HE\F:>4KE)$
M)^H:0!1110!%)(X'`8Y]JI:AJEQ9QEUM[B8CM''N)_.M*B@#SS7/C!?6-P;8
M^"O&=]')\C-#80O%@]<[I1Q^%4]/^%O@[Q;(MS>?#/1XYR=^Z^T"U\P,1C.<
M-S@UZ?14SA"7Q*Y,HI_$KF1X;\-V'A:Q-MIFF6>F6['=Y5K;)`F?]U0!5_3[
M"+3;2.W@B2""!1''%&H1(U`P%`'``'&!Z58HII)*R'RH*I>(?#EAXMTB;3]4
ML;/4K"X`$MM=P+/#+@AAN1@0<$`\CJ`:NT4QF1X/\`:'\/K*6VT+1M)T6WG?
MS)(M/LX[5)&P!N(0`$X`&3Z5KT44`0:GID&LV$]I=PQ7-M<QM#-#*@DCE1AA
ME93P5()!!X(-200+;QJB`*J@*JJ,!0.@`I]%`!6#\0?A=X:^+6BQZ;XJ\/:'
MXET^*9;A+75M/BO84E7.UPDJLH89.#C(S6]10!%964>GVT<$,:10PH(XXXU"
MI&H&`H`X``XP*EHHH`RO%W@;1?'^G)9Z[I&EZU:QR>:D-_:1W,:O@@,%<$`X
M)&?<T_PIX-TGP+I0L-%TS3M(L58N+>QM4MX0QZMM0`9/<XK2HH`*S?%W@_2O
M'_AR[T?7=,T[6M)OT\NYL;^V2YMKE<@[7C<%6&0#@@]*TJ*`,_PKX3TSP-H%
MKI.BZ=8:1I5BGEVUE8VZ6]O;KG.U(T`51D]`!6A110`CIO&#_+.:YOP/\&O"
M7PQADC\->&/#GAU)9WN773-,@LP\K@!Y#Y:C+,``6ZG`S72T4`%(Z[L<\BEH
MH`KZ5I-MH6GP6=G;P6EI:QK%#!#&(XX4`P%51P`!P`!@58HHH`R/'7P_T+XG
M^&KC1?$FBZ3X@TBZQYUCJ=G'=VTV#D;HY`5;!`(R.HJYH>A6?AG2;;3].M+6
MPL+*)8;>VMHEAA@C485$10`J@<``8%6Z*`"J'B?POIOC70+K2M8T^QU73+Z,
MQ7-G>6Z7%O<(>JO&X*L/8@BK]%`&7X+\#Z-\./#=KHWA_2=,T+2+$%;:QTZT
6CM;:W!))"1Q@*H))/`ZFM2BB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
